Purchase this article with an account.
Rie Osaka, Chieko Shiragami, Aoi Ono, Saki Manabe, Yukari Takasago, Mamoru Kobayashi, Ayana Yamashita, Kazuyuki Hirooka; One-year Outcomes of Fixed Treatment of Intravitreal Aflibercept for Exudative Age-related Macular Degeneration and the Factor of Visual Prognosis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):811.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration (AMD), and potential predictors of visual outcome.
Fifty-two eyes of 52 treatment-naive AMD patients received IVA bimonthly following 3 monthly loading doses prospectively. Primary endpoints were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and secondary outcomes included changes in subfoveal choroidal thickness (SCT), macular atrophy (MA), and average retinal sensitivity (AS) at 12 months compared with baseline. Potential predictors of change in BCVA were examined.
Four patients dropped out, thus 48 were examined. Mean logMAR BCVA improved significantly (P = .008). CRT was significantly reduced at 12 months, as was SCT (P < .001). At 12 months, 72.3% exhibited a dry macula, and of these MA was evident in 20.0%. Mean AS at 12 months (17.6 dB) was significantly improved compared to baseline (15.4 dB) (P = .027). BCVA was significantly worse in cases with MA involving the fovea. Age and CRT at baseline were significant predictors of BCVA at 12 months.
IVA administered over 1 year improved BCVA, AS, and morphological characteristics. Age, baseline CRT, and MA involving the fovea were identified as predictors of BCVA.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only